Drug Profile
TEV 45478
Alternative Names: TEV-45478Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-II for Non-alcoholic steatohepatitis in Israel (PO) (Teva Pharmaceutical pipeline, February 2022)
- 04 Jan 2018 Teva withdraws a phase II trial for Non-alcoholic steatohepatitis in Israel, prior to enrolment due to business decisions (NCT02769091)
- 16 Nov 2016 Teva suspends enrolment in a phase II trial for Non-alcoholic steatohepatitis in Israel, due to business decisions (NCT02769091)